AbbVie's JAK Inhibitor "Upatinib" Approved in China for the Third Indication

Article source: Medical Cube Info

On April 6, the official website of the Food and Drug Administration showed that another marketing application for AbbVie’s upadatinib extended-release tablets was approved for the treatment of active patients with poor efficacy or intolerance to one or more DMARDs.

This is the third indication after the product was approved for the treatment of moderately to severe active rheumatoid arthritis and moderate to severe atopic dermatitis in China, and it has become the only targeted therapy approved in China for the treatment of PsA

Upatinib (trade name: Rinvoq) is a once-daily oral JAK1 inhibitor developed by AbbVie.

Source: NextPharma

This approval is mainly based on data from the Phase III clinical study SELECT-PsA 1, which evaluated the efficacy, safety and tolerability of upadatinib extended-release tablets in patients with PsA

Since its listing, the sales of Upatinib have risen rapidly.